Novo Nordisk A/S (NYSE:NVO) vs. Nutriband (NASDAQ:NTRB) Head-To-Head Contrast

Nutriband (NASDAQ:NTRB) and Novo Nordisk A/S (NYSE:NVO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Valuation and Earnings

This table compares Nutriband and Novo Nordisk A/S”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04 million	33.56	-$8.23 million	($2.58)	-2.18
Novo Nordisk A/S	$46.80 billion	4.53	$15.51 billion	$4.09	11.60

Novo Nordisk A/S has higher revenue and earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nutriband and Novo Nordisk A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutriband	-448.25%	-112.64%	-97.86%
Novo Nordisk A/S	35.36%	61.20%	21.49%

Volatility & Risk

Nutriband has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Nutriband and Novo Nordisk A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1	1	0	0	1.50
Novo Nordisk A/S	1	14	4	0	2.16

Novo Nordisk A/S has a consensus price target of $64.94, suggesting a potential upside of 36.85%. Given Novo Nordisk A/S’s stronger consensus rating and higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Nutriband.

Insider and Institutional Ownership

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Novo Nordisk A/S beats Nutriband on 9 of the 13 factors compared between the two stocks.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.